List of Therapeutic Companies in Indiana - 15

Adipo Therapeutics, an Indiana biotechnology company, is developing polymer-based, Notch-inhibiting nanoparticles that are injected directly into adipose (fat) tissue to induce browning, or white-to-beige adipocyte transformation. The goal? Reducing weight and restoring metabolic balance for millions of people living with diabetes.

BioPoly® was established to provide a treatment option for painful cartilage lesions between the extremes of biological solutions and total joint replacement. Utilizing a patented material that is self-lubricating for improved wear properties (via a biological enhancement with Hyaluronic Acid) the BioPoly® RS devices are uniquely designed to replace only the damaged cartilage. Therefore, patients can quickly recover and return to pain-free, active lifestyles. BioPoly® RS devices are currently available for femoral condyle, trochlear facets, trochlear groove, patella, and humeral head applications. Patients out to >10 years have experienced a significant reduction in pain and have shown improved quality of life. Additional orthopedic applications are currently in development. BioPoly® serves healthcare professionals and their patients throughout the world from our headquarters in Fort Wayne, Indiana, USA.

EIG's mission is to develop highly accurate and non-invasive multi-omic molecular testing solutions for complex diseases like cancer. The company has developed a Multi-omic Integration Platform that combines detection of DNA, RNA, protein and metabolite targets into a single assay. This breakthrough approach transforms the field of molecular diagnostics by offering unparalleled accuracy with comprehensive insights for early disease detection. www.earlyisgood.com.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin’s lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Eradivir is a biotech company that aims to develop a non-immunological targeting agent for use against the virus that causes COVID-19. The company has discovered small bispecific drugs that engage both cytotoxic immune cells and the virus. Binding of the drug to the virus leads to the destruction of the virus by the immune system.

Gate Neurosciences is on a mission to develop a new generation of therapies for the hundreds of millions of people worldwide suffering from neuropsychiatric and cognitive disorders. We are dedicated to advancing novel, safe, and rapid-acting drug mechanisms that address underlying disease biology by enhancing synaptic function, strengthening neuronal connections, and restoring healthy brain signaling. Our approach focuses on precision psychiatry and evidence-driven insights, and is based on learnings from extensive clinical, preclinical, and translational data across thousands of patients with our molecules. By rethinking what’s possible, we’re creating hope for better mental health treatments and better lives.

Grannus is a biotech startup based on the technological discoveries of Notre Dame Scientists Dr. Brian Blagg and Dr. Sanket Mishra, and the administration of pharmaceutical company that has the... Meanwhile, McDonnell has high-profile.

Kovina Therapeutics is a preclinical stage biotechnology company developing first-in-class antiviral therapeutics designed to treat cancers and pre-malignant infections caused by Human Papillomavirus (HPV)

MBX Biosciences, Inc. is a clinical stage biopharmaceutical company pioneering investigational Precision Endocrine Peptides (PEPs™). PEPs are designed to overcome key limitations of native peptide therapeutics to deliver superior pharmacologic properties. MBX is advancing a pipeline of PEP candidates to address the unmet needs of people with endocrine disorders. The company’s lead product candidate, MBX 2109 for the treatment of hypoparathyroidism, is currently in a Phase 1 clinical trial. Members of MBX’s leadership team have collaborated over several decades on the discovery, development, and commercialization of highly successful endocrine therapeutics including Forteo® and Humalog®. The company is supported by leading life science investors including Frazier Life Sciences, New Enterprise Associates and OrbiMed.

MindX Sciences, Inc. is the future of mental health management by providing the only mental health solution that gives providers the confidence of the correct diagnosis and proper treatment choice. We bring objectivity and precision to mental health management. Our unique and proprietary RNA blood tests assess disease state and disease risk and help with diagnosis and tracking of response to treatment. Additionally, our tests also match patients to medications and nutraceuticals based on their biology, in a precise and personalized way. Reach out to us at info@mindxsciences.com

Neurodon - We began as a team of scientists building upon an established, yet not fully explored, way to approach disease: cellular stress and calcium imbalance in the cell. Cellular stress and calcium imbalance have been shown to be at the root of a wide range of diseases. For years, we have been researching how activating a calcium pump called SERCA in the cell can restore calcium balance and reverse cellular stress. Our breakthrough therapeutics are now under preclinical development for diseases such as diabetes, Alzheimer’s, Parkinson’s, Duchenne muscular dystrophy, and other rare diseases. We have formed impressive partnerships to help achieve our vision of changing the lives of patients suffering from debilitating diseases.

Scioto Biosciences is a clinical stage biotech company dedicated to innovative research and discovery in the field of microbiome therapeutics. The companies treatment focuses on activating beneficial bacteria to promote healing.

Syndeio Biosciences (from the Ancient Greek word “to connect”) is a clinical-stage biotechnology company developing therapies to restore and enhance synaptic health in CNS disorders. The company’s proprietary Boost™ Synapse Pharmacology Platform combines electrophysiology, behavior, and human neuronal network assays to predict clinical outcomes with unprecedented accuracy. Syndeio’s clinical pipeline includes lead asset, zelquistinel, currently in Phase 2 development for major depressive disorder and will soon be entering an industry-first biomarker study in Alzheimer’s disease, and apimostinel, currently in an investigator-led phase 2 study for acute depression. The company is headquartered in Indianapolis, IN with research laboratories in Menlo Park, CA & Evanston, IL focused on advancing the Boost™ Synapse Pharmacology Platform.

Theratome Bio is a pre-clinical company developing a platform of cell-free biologics. The therapeutics cover multiple areas of unmet medical need, and offer advantages over cell-based therapies, including off-the-shelf administration, convenient freezer temperature storage and delivery, and immediate bioavailability. Current therapeutic areas under development are ischemic brain injury, concussion, acute kidney injury, and increasing the shelf life of donor organs and tissues.

Zimmer Biomet is a global medical technology leader with a comprehensive portfolio designed to maximize mobility and improve health. We advance our mission to alleviate pain and improve the quality of life for patients around the world with our innovative products and suite of integrated digital and robotic technologies leverage data, data analytics and artificial intelligence. Founded in 1927 and based in Warsaw, Zimmer Biomet has operations in more than 25 countries and sales in more than 100 countries. We maintain world-class scientific facilities and resources and collaborate with leading clinicians and researchers around the world. Awards and Recognitions • Forbes Best-in-State Employers in Indiana (2020 and 2021) • Newsweek's America's Most Responsible Companies (2021) • Military Friendly Employer by VIQTORY (2019 and 2020) • Best Employer Award: China (2011-2021) • Great Place to Work: Brazil (2021) • Indiana Manufacturers Association Manufacturing Excellence Awards (2020) • ComputerWorld's "Best Places to Work in IT" (2018-2020) • Forbes Global 2000 (2020 and 2021) • Fortune 500 List (2020 and 2021) • Medical Device and Diagnostic Industry MedTech Company of the Year (2019)